US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HORIZON KINETICS MEDICAL ETF

34.96

-0.1032-0.29%

Post-market: 35.000.0428+0.12%16:10 EDT

Volume:2K

Turnover:66.28K

Market Cap:16.43M

PE:- -

High:35.10

Open:35.10

Low:34.96

Close:35.06

52wk High:37.90

52wk Low:28.87

Shares:469.95K

Float Shares:469.95K

Volume Ratio:0.73

T/O Rate:0.40%

Dividend:0.41

Dividend Rate:1.17%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Novartis AG Falls Wednesday, Outperforms Market

Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says

MT Newswires Live

Novartis Shouldn't Rush to Cover Upcoming Patent Expirations

Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress

Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call

THOMSON REUTERS

Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call

THOMSON REUTERS

Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030

IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress

ProQR Therapeutics doses first participant in AX-0811 clinical trial

Bayer initiates Phase II study of BAY 3670549 in patients with AFib

Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting

Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027

Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247

RBC Initiates Novartis at Sector Perform With CHF120 Price Target

MT Newswires Live

Evotec initiates clinical trial evaluating JST-018

Novartis's Stock Selloff Looks Overdone

Novartis Faces Sales Hole in Early 2030s After Trial Setback

Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating

How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data

Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigreclipse.com/stock/MEDX/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"MEDX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","market":"US","secType":"STK","nameCN":"HORIZON KINETICS MEDICAL ETF","latestPrice":34.9572,"timestamp":1789156800000,"preClose":35.0604,"halted":0,"volume":1892,"hourTrading":{"tag":"盘后","latestPrice":35,"preClose":34.9572,"latestTime":"16:10 EDT","volume":8,"amount":279.3488,"timestamp":1789157404699,"change":0.0428,"changeRate":0.001224,"amplitude":0},"delay":0,"changeRate":-0.002943491802717626,"floatShares":469946,"shares":469946,"eps":0,"marketStatus":"Market Closed","change":-0.1032,"latestTime":"09-11 16:00:00 EDT","open":35.1,"high":35.1,"low":34.9572,"amount":66279,"amplitude":0.004073,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":35.0604,"sharesOutstanding":569946,"nav":35.04,"aum":16466907.84,"dividendRate":0.011734,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":35,"preClose":34.9572,"latestTime":"16:10 EDT","volume":8,"amount":279.3488,"timestamp":1789157404699,"change":0.0428,"changeRate":0.001224,"amplitude":0},"volumeRatio":0.7312359869705651},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MEDX\",,,,,undefined,":{"symbol":"MEDX","floatShares":469946,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.7312359869705651,"shares":469946,"dividePrice":0.4102,"high":35.1,"amplitude":0.004073,"preClose":35.0604,"low":34.9572,"week52Low":28.8652,"pbRate":"--","week52High":37.9,"institutionHeld":0,"latestPrice":34.9572,"eps":0,"divideRate":0.011734,"volume":1892,"delay":0,"ttmEps":0,"open":35.1,"prevYearClose":33.2024,"prevWeekClose":36.6906,"prevMonthClose":36.417,"prevQuarterClose":36.7138,"fiveDayClose":37.0834,"twentyDayClose":35.9599,"sixtyDayClose":34.1895},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MEDX\",params:#limit:5,,,undefined,":[{"date":"2025-12-23","symbol":"MEDX","amount":0.4088,"announcedDate":"2025-12-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-23","defaultRemindTime":1766500200000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-24","payableDate":"2025-12-23","currency":"USD","dateTimestamp":1766466000000,"payDate":"2025-12-24"},{"date":"2024-12-24","symbol":"MEDX","amount":0.502335,"announcedDate":"2024-12-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-24","defaultRemindTime":1735050600000,"name":"HORIZON KINETICS MEDICAL ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-26","payableDate":"2024-12-24","currency":"USD","dateTimestamp":1735016400000,"payDate":"2024-12-26"},{"date":"2023-12-27","symbol":"MEDX","amount":1.379798,"announcedDate":"2023-12-26","type":"dividend","market":"US","newRecordDate":"2023-12-28","defaultRemindTime":1703687400000,"name":"HORIZON KINETICS MEDICAL ETF","recordDate":"2023-12-29","payableDate":"2023-12-28","currency":"USD","dateTimestamp":1703653200000,"payDate":"2023-12-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MEDX\",market:\"US\",,,undefined,":[{"executeDate":"2023-12-27","recordDate":"2023-12-28","paymentDate":"2023-12-29","value":1.379798,"currency":"USD"},{"executeDate":"2024-12-24","recordDate":"2024-12-24","paymentDate":"2024-12-26","value":0.502335,"currency":"USD"},{"executeDate":"2025-12-23","recordDate":"2025-12-23","paymentDate":"2025-12-24","value":0.4088,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MEDX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MEDX\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666531005","title":"Novartis AG Falls Wednesday, Outperforms Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2666531005","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666531005?lang=en_us&edition=fundamental","pubTime":"2026-09-10 00:15","pubTimestamp":1788970500,"startTime":"0","endTime":"0","summary":"This article was automatically generated using Dow Jones technology.Shares of Novartis AG  slipped 0.1% to CHF111.66 Wednesday on what proved to be an overall unfavorable trading session for the stock market, with the Swiss Market Index SMI Index  falling 1.8% to 13,804.70.Novartis AG closed CHF21.02 below its 52-week high of CHF132.68, which the company achieved on September 3, 2026.Trading volume was 4,314,570, compared to the 50-day average trading volume of 2,451,167.Data source: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE0002141913.USD","BK4532","IE00BJJMRZ35.SGD","NVS","BK4588","IE00B2B36J28.USD","IE00B4R5TH58.HKD","PPH","BK4578","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","LU0320765489.SGD","IE00BJT1NW94.SGD","LU0070302665.USD","BK4007","IE0009355771.USD","LU0211331839.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539005","title":"Dyne Therapeutics Myotonic Dystrophy Approach Remains Differentiated, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539005","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539005?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:10","pubTimestamp":1788966641,"startTime":"0","endTime":"0","summary":"Dyne Therapeutics  investment thesis remains intact despite a setback for Novartis  in a phase 3 trial for myotonic dystrophy type 1, as differences in drug targeting, payload and clinical strategy could lead to different outcomes, RBC Capital Markets said in a Tuesday note.According to the analysts, Dyne's approach uses an antibody fragment rather than a full-length antibody, an antisense oligonucleotide rather than small interfering RNA, and a six month primary endpoint versus 12 months for Novartis' trial.RBC said Dyne remains confident in its phase 3 study, with data expected in Q1 2027.Dyne is also running a confirmatory phase 3 study using the five times sit-to-stand test as its primary endpoint, providing a second opportunity to achieve statistical significance, the note said.The analysts also see a potential catalyst in Dyne's DMD51 program, with a US Food and Drug Administration decision expected Jan. 21, 2027.RBC maintained its outperform rating on Dyne Therapeutics and lower","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0208291251.USD","IE00BFTCPJ56.SGD","NVS","BK4139","IE0002141913.USD","LU0211331839.USD","PPH","BK4585","LU0070302665.USD","BK4532","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","MEDX","BK4007","BK4505","BK4588","IE00B2B36J28.USD","LU0320765489.SGD","DYN","IE00B4R5TH58.HKD","BK4578","IE0009355771.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253906","title":"Novartis Shouldn't Rush to Cover Upcoming Patent Expirations","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253906","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253906?lang=en_us&edition=fundamental","pubTime":"2026-09-09 23:07","pubTimestamp":1788966420,"startTime":"0","endTime":"0","summary":"1507 GMT - Recent clinical-trial setbacks mean Novartis needs to be near-flawless in bringing the rest of its pipeline to the market or look for deals, but the Swiss drugmaker shouldn't rush it, RBC Capital Markets analysts say in a research note. \"Shares have pulled back from all-time highs, but we see no urgency to act,\" the analysts say. The failures of cardiovascular and neuromuscular drugs pelacarsen and del-desiran raise the bar for Novartis's pipeline, given that these were two important candidates to offset sales lost to upcoming patent expirations, they add. RBC starts coverage on the stock with a sector perform recommendation and a target price of 120 Swiss francs. Shares fall 0.3% to 111.44 francs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","IE00BJJMRZ35.SGD","BK4578","LU0320765489.SGD","NVS","BK4532","LU0208291251.USD","IE00BFTCPJ56.SGD","PPH","MEDX","IE0002141913.USD","IE0009355771.USD","LU0070302665.USD","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253912","title":"Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253912?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:44","pubTimestamp":1788965040,"startTime":"0","endTime":"0","summary":"Tyra Biosciences is taking on Johnson & Johnson to develop a next-generation treatment common type of bladder cancer, but the latest data for its experimental pill failed to inspire confidence.The Pha","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","LU2756315664.SGD","LU2403377893.USD","LU0122379950.USD","SGXZ80539844.SGD","LU1291159041.SGD","LU2750360641.GBP","IHE","BMED","IE000SO60NU8.SGD","FTXH","IXJ","VHT","LU1043141123.HKD","LU2468319806.SGD","TYRA","IE00B7SZLL34.SGD","LU1244550577.SGD","LU0203345920.USD","BK4550","IE000M9KFDE8.USD","PJP","RXL","BK4139","LU0203347892.USD","LU1196500208.SGD","SG9999002232.USD","SG9999002224.SGD","TRUH","FHLC","LU1551013342.USD","LU2430703178.SGD","LU0426417589.USD","IE00BLSP4239.USD","URGN","LU1280957306.USD","MEDX","IE000F7OJYX1.SGD","IE00BFXG1179.USD","JDOC","XLV","BK4532","GDOC","SGXZ57979304.SGD","LU1914381329.SGD","IYH","IE0009355771.USD","LU1032466523.USD","LU2213496289.HKD","LU0289739699.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539473","title":"Abbvie Exec Says Strong Balance Sheet and Long Growth Runway Allow Company to Consider Both Early- and Late-Stage Business Development Opportunities - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539473","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539473?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","FHLC","LU1732799900.SGD","LU0114720955.EUR","LU0553294199.USD","LU1236620834.HKD","LU1267930490.SGD","PJP","LU0738911758.USD","LU0882574055.USD","LU0029864427.USD","LU0122379950.USD","SG9999003800.SGD","IXJ","LU0912757837.SGD","LU2112291526.USD","IYH","LU0234572021.USD","IE00B19Z3B42.SGD","LU0289961442.SGD","IE00BLSP4239.USD","IE00BLSP4452.SGD","VHT","LU0170899867.USD","TRUH","LU0417517546.SGD","XLV","LU2089984988.USD","IE000MB6IJN5.SGD","GLAM","LU1989772840.SGD","LU0456855351.SGD","LU0965509010.AUD","JDOC","PPH","LU0708994859.HKD","LU2237443978.SGD","LU0158827948.USD","MEDX","RXL","AGNG","FTXH","BK4566","LU1934455277.USD","SG9999011175.SGD","LU1037948541.HKD","SG9999015986.USD","LU0689626769.HKD","ABBV","LU2089284900.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666539343","title":"Abbvie Exec Says Expects Approval of Subcutaneous Crohn's Disease Treatment in Q4 - Conf Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2666539343","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666539343?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:25","pubTimestamp":1788963943,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260909:nFWN45113M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["FHLC","LU0820561818.USD","LU0472753341.HKD","LU1585245621.USD","LU1236620834.HKD","LU2347655073.USD","IE00B19Z3581.USD","LU1929549753.HKD","PJP","LU0965508806.USD","LU0882574055.USD","LU0726765562.USD","LU0122379950.USD","LU0128525929.USD","IXJ","IE00BVYPNW00.USD","LU0912757837.SGD","IYH","IE00B19Z3B42.SGD","LU0689472784.USD","IE00BLSP4452.SGD","LU1003077747.HKD","VHT","TRUH","XLV","LU2125909593.SGD","LU2237443895.HKD","LU0098860793.USD","GLAM","LU1093756325.SGD","PPH","IE000BZT7R73.USD","IE00BJJMRZ35.SGD","JDOC","IE00BFTCPJ56.SGD","IE0002270589.USD","LU1923622614.USD","LU0310799852.SGD","MEDX","RXL","AGNG","LU0198837287.USD","FTXH","BK4566","IE00BDGV0183.EUR","LU1037948541.HKD","LU2129689431.USD","IE0000B7K699.USD","ABBV","SG9999015986.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107437767","title":"Henlius CEO Zhu Jun: Systematic Globalization Aims for Long-Term Gains, Innovative Drug Revenue Set to Surpass Biosimilars by 2030","url":"https://stock-news.laohu8.com/highlight/detail?id=1107437767","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107437767?lang=en_us&edition=fundamental","pubTime":"2026-09-09 21:11","pubTimestamp":1788959461,"startTime":"0","endTime":"0","summary":"During the 2026 Yabuli Forum Summer Annual Meeting, Henlius (02696.HK) Executive Director and CEO Dr. Zhu Jun outlined the company's \"systematic globalization\" strategy in an in-depth conversation,...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000306701.USD","BK1574","MEDX","HK0000320264.USD","LNGR","06978","BK4585","LU2272731782.SGD","XPH","IBB","LU1992135399.USD","BK4588","LU2322448791.USD","02696","HK0000165453.HKD","IBBQ","LU2272731865.HKD","LU2322448957.HKD","LU2272731600.USD","PPH","LU2473716301.USD","IE00B5TLWC47.USD","159992","LU1992135472.HKD","HK0000320223.HKD","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666907533","title":"IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666907533","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666907533?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:30","pubTimestamp":1788957000,"startTime":"0","endTime":"0","summary":"Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept.  09, 2026 (GLOBE NEWS","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358657/0/en/imunon-announces-full-agenda-and-speaker-lineup-ahead-of-2026-r-d-day-highlighting-imnn-001-clinical-progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065732104.USD","IMNN","MEDX","GDOC","BK4097","IDNA","HYLG","NVIB","PRGS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538091","title":"ProQR Therapeutics doses first participant in AX-0811 clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538091","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538091?lang=en_us&edition=fundamental","pubTime":"2026-09-09 20:15","pubTimestamp":1788956125,"startTime":"0","endTime":"0","summary":"ProQR Therapeutics (PRQR) announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. Publi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/proqr-therapeutics-doses-first-participant-in-ax-0811-clinical-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IDNA","AX","LENZ","LU1861217088.USD","BK4007","BK4211","BK4195","BK4139","LU2360107671.USD","MEDX","NVIB","PRQR","BK4539","GDOC","LU1861220207.SGD","HYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666538313","title":"Bayer initiates Phase II study of BAY 3670549 in patients with AFib","url":"https://stock-news.laohu8.com/highlight/detail?id=2666538313","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666538313?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:45","pubTimestamp":1788954315,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced the initiation of a global Phase II clinical trial evaluating BAY 3670549, an investigational highly selective G-protein-co...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-initiates-phase-ii-study-of-bay-3670549-in-patients-with-afib-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BAY","BAYRY","BK4007","MEDX","NVIB","HYLG","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666858794","title":"Fate Therapeutics Announces Encore Clinical Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate at the CCR – West 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2666858794","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666858794?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"SAN DIEGO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358477/24675/en/fate-therapeutics-announces-encore-clinical-data-presentation-of-ft819-off-the-shelf-car-t-cell-product-candidate-at-the-ccr-west-2026-meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLE","IDNA","GDOC","MEDX","BK4139","HYLG","BK4077","NVIB","CCR","BMED","FATE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666587949","title":"Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666587949","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666587949?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improve","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358458/0/en/opus-genetics-announces-positive-low-dose-cohort-1-data-from-phase-1-2-clinical-trial-of-opgx-best1-and-successful-fda-type-c-meeting-with-potential-phase-3-dosing-in-2027.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ARB","GDOC","HYLG","BK4585","MEDX","BK4588","NVIB","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666558799","title":"Satellos Announces Forazapadin as Assigned International Nonproprietary Name for Lead Drug Candidate, SAT-3247","url":"https://stock-news.laohu8.com/highlight/detail?id=2666558799","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666558799?lang=en_us&edition=fundamental","pubTime":"2026-09-09 19:00","pubTimestamp":1788951600,"startTime":"0","endTime":"0","summary":"TORONTO, Sept.  09, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience (Nasdaq: MSLE, TSX: MSCL), a clinical-stage drug development company developing life-improving medicines to treat degenerative muscle d","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/09/3358479/0/en/satellos-announces-forazapadin-as-assigned-international-nonproprietary-name-for-lead-drug-candidate-sat-3247.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","HYLG","BMED","INN","GDOC","SAT","IDNA","NVIB","MEDX","BK4218","DBB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666847965","title":"RBC Initiates Novartis at Sector Perform With CHF120 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2666847965","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666847965?lang=en_us&edition=fundamental","pubTime":"2026-09-09 18:29","pubTimestamp":1788949792,"startTime":"0","endTime":"0","summary":"Novartis's (NVS) Swiss stock has an average rating of hold and mean price target of CHF125.60, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0320765489.SGD","IE00B2B36J28.USD","BK4532","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","NVS","MEDX","IE00BJJMRZ35.SGD","LU0211331839.USD","PPH","LU0070302665.USD","BK4578","IE00BJT1NW94.SGD","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666589922","title":"Evotec initiates clinical trial evaluating JST-018","url":"https://stock-news.laohu8.com/highlight/detail?id=2666589922","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666589922?lang=en_us&edition=fundamental","pubTime":"2026-09-09 17:15","pubTimestamp":1788945324,"startTime":"0","endTime":"0","summary":"Evotec (EVO) announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/evotec-initiates-clinical-trial-evaluating-jst-018-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HYLG","GDOC","IDNA","BK4121","NVIB","MEDX","EVO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666854435","title":"Novartis's Stock Selloff Looks Overdone","url":"https://stock-news.laohu8.com/highlight/detail?id=2666854435","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666854435?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:24","pubTimestamp":1788942240,"startTime":"0","endTime":"0","summary":"0823 GMT - Novartis's stock selloff on the failure of a neuromuscular drug in a clinical trial looks overdone and upcoming study results could be more positive for the Swiss drugmaker, Citi analysts say in a research note. The company reiterated its 2025-2030 outlook and trial setbacks for experimental neuromuscular and heart drugs del-desiran and pelacarsen are partially mitigated by the success of its remibrutinib medicine in a multiple sclerosis study, the analysts say. Full data for the MS study and results from another trial for the same drug in skin condition hidradenitis suppurativa could play in Novartis's favor, they add. Citi cuts its target price on Novartis stock to 135 Swiss francs from 142 francs. Shares fall 1.1% to 110.54 francs, after closing 11% lower Tuesday.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0320765489.SGD","IE00B2B36J28.USD","BK4532","BK4007","LU0208291251.USD","IE00BFTCPJ56.SGD","IE0002141913.USD","BK4588","NVS","MEDX","IE00BJJMRZ35.SGD","LU0211331839.USD","PPH","LU0070302665.USD","BK4578","IE00BJT1NW94.SGD","IE0009355771.USD","BK4585","IE00B4R5TH58.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666158379","title":"Novartis Faces Sales Hole in Early 2030s After Trial Setback","url":"https://stock-news.laohu8.com/highlight/detail?id=2666158379","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666158379?lang=en_us&edition=fundamental","pubTime":"2026-09-09 16:01","pubTimestamp":1788940860,"startTime":"0","endTime":"0","summary":"0801 GMT - Novartis's latest clinical-trial setback raises questions about the Swiss drugmaker's acquisition track record and leaves a sales hole to be plugged in the early 2030s, Deutsche Bank's Emmanuel Papadakis says in a research note. News that drug candidate del-desiran missed the target of a late-stage study in rare neuromuscular disorder known as myotonic dystrophy type 1 came shortly after cardiovascular drug pelacarsen failed another trial. Del-desiran was the first proof point for the recent $12 billion Avidity acquisition, the analyst says. Moreover, it leaves a hole to be addressed in the early 2030s when big drugs like Cosentyx, Kisqali and Kesimpta lose patent protection, he adds. Deutsche Bank cuts its recommendation on Novartis stock to hold from buy and trims its target price to 120 Swiss francs from 140 francs. Shares fall 0.8% to 110.86 francs.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Novartis Faces Sales Hole in Early 2030s After Trial Setback","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0211331839.USD","IE00BJJMRZ35.SGD","BK4578","LU0320765489.SGD","NVS","BK4532","LU0208291251.USD","IE00BFTCPJ56.SGD","PPH","MEDX","IE0002141913.USD","IE0009355771.USD","LU0070302665.USD","BK4585","IE00BJT1NW94.SGD","IE00B2B36J28.USD","IE00B4R5TH58.HKD","BK4588","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189130455","title":"Amgen Shares Plunge to Decade Low After Rival Drug Trial Fails, BMO Cuts Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1189130455","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1189130455?lang=en_us&edition=fundamental","pubTime":"2026-09-09 14:48","pubTimestamp":1788936492,"startTime":"0","endTime":"0","summary":"Amgen shares tumbled more than 10% on Tuesday, marking their worst single-day decline since 2016, after Novartis AG revealed that a heart disease therapy it is developing with Ionis Pharmaceuticals...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMGN","LU0868494617.USD","BK4585","LU0889565916.HKD","IE0002141913.USD","LU1983299246.USD","BIB","BK4532","IE00BJJMRZ35.SGD","LU2468319806.SGD","NVS","LU2242646821.SGD","BK4588","LU2242652126.USD","LU2089984988.USD","BK4581","IE00B2B36J28.USD","LU0058720904.USD","SG9999001440.SGD","LU1023059063.AUD","IE00B4R5TH58.HKD","PPH","BK4566","BK4599","LU1061106388.HKD","BK4534","BK4578","LU0109394709.USD","MEDX","IE00BFTCPJ56.SGD","LU0208291251.USD","PBE","LU0320765489.SGD","BK4533","PJP","LU2112291526.USD","LU0320765992.SGD","IBB","IE00BJT1NW94.SGD","BBH","LU0070302665.USD","BK4139","BK4007","TBXU","LU0289739699.SGD","LU1571399168.USD","IE0009355771.USD","LU0211331839.USD","IBBQ","LU0122379950.USD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186275720","title":"How Traditional Chinese Medicine Is Moving From Ancient Recipes to Evidence-Based Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1186275720","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186275720?lang=en_us&edition=fundamental","pubTime":"2026-09-09 07:41","pubTimestamp":1788910867,"startTime":"0","endTime":"0","summary":"Traditional Chinese Medicine (TCM) has long been built on the accumulated wisdom of generations of physicians. However, when measured against the rigorous standards of modern medicine, the industry...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK4159","BK1161","06978","BK1574","MEDX","LNGR","RCT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666370615","title":"Atai Beckley Holds Shareholder Meeting, Quorum Met with 65.6% Shares Represented","url":"https://stock-news.laohu8.com/highlight/detail?id=2666370615","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666370615?lang=en_us&edition=fundamental","pubTime":"2026-09-09 05:10","pubTimestamp":1788901814,"startTime":"0","endTime":"0","summary":"Atai Beckley holds shareholder meeting, quorum met with 65.6% shares representedAtai Beckley held a virtual special shareholder meeting on Sept. 8, 2026 to vote on a merger agreement with Eli Lilly.Sh","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260908:nNDL1JLSHz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2213496289.HKD","FHLC","LU1548497426.USD","LU2237443622.USD","BK4516","LU0210536198.USD","LU1623119135.USD","LU0096364046.USD","SGXZ31699556.SGD","XLV","LU0158827781.USD","LU0820561818.USD","ILDR","IE00B1BXHZ80.USD","LU0823434583.USD","IE00BK4W5L77.USD","BK4539","IE0005OL40V9.USD","LU0943347566.SGD","IXJ","BK4533","GDOC","LU2756315318.SGD","LU2357305700.SGD","LU0316494557.USD","SG9999001176.USD","IE00BJJMRZ35.SGD","LU1868836757.USD","JDOC","LU0106261372.USD","LU2237443895.HKD","LU0354030438.USD","LU2324357040.USD","LU2471134796.USD","LU2063271972.USD","IE00BFTCPJ56.SGD","TMED","LU2552382215.SGD","LU1551013342.USD","LU0385154629.USD","LU0345770308.USD","LU1127390331.HKD","LU0061475181.USD","LU1323610961.USD","LU0203202063.USD","LU2471134879.HKD","LU0114720955.EUR","LU0889565916.HKD","LU1093756168.USD","LU1712237335.SGD","LU2111349929.HKD","IE0004445015.USD","SG9999014906.USD","IE00BJJMRY28.SGD","LU2108987350.USD","LU2265009873.SGD","LU2491050071.SGD","SG9999013999.USD","SGXZ99366536.SGD","CANC","IE00BFSS8Q28.SGD","LU0689472784.USD","LU1720051017.SGD","LU2168564065.EUR","LU2237443382.USD","SG9999014898.SGD","LU2750360997.AUD","LU2023251221.USD","IE00BKPKM429.USD","LU0787776722.HKD","LU1064131342.USD","LU0203201768.USD","LU2087625088.SGD","SG9999017495.SGD","RXL","LU2089284900.SGD","LU0786609619.USD","BK4581","LU0174119429.USD","LU2417539215.USD","LU0289739699.SGD","BK4585","LU2361044865.SGD","LU0882574139.USD","IE00B4JS1V06.HKD","VHT","LU1814569148.SGD","PJP","LU2211815571.USD","LU0820561909.HKD","LU2023250504.SGD","LU2468319806.SGD","LU2491050154.USD","BK4588","LU0471298777.SGD","LU0432979614.USD","LU2746668461.USD","LU0256863811.USD","LU0122379950.USD","LU0266013472.USD","SG9999018857.SGD","LLII","LU0109391861.USD","LU0006306889.USD","LU1868836914.USD","LU2491049909.HKD","LU2471134952.CNY","LU0353189763.USD","LU1551013425.SGD","LU2271345857.HKD","LU1868837136.USD","SG9999015952.SGD","LU0354030511.USD","LU1868837300.USD","SGXZ51526630.SGD","LU0882574055.USD","ATAI","LU2461242641.AUD","LU2168563687.JPY","BK4534","LU2361045086.USD","LU0198837287.USD","LU2462591350.SGD","LU1061106388.HKD","LU1989771016.USD","SG9999014880.SGD","SG9999018865.SGD","IE00BK4W5M84.HKD","LU1023059063.AUD","LU1917777945.USD","LU2471134523.USD","IE00B775H168.HKD","LU1291159041.SGD","LU2264538146.SGD","LU0353189680.USD","LU0158827948.USD","LU1280957306.USD","LU2237443549.SGD","LU0094547139.USD","MHIP","LU0708995401.HKD","LLYZ","IE0004445239.USD","LU0323591593.USD","LU0672654240.SGD","LU1145028129.USD","THNR","LU0225283273.USD","FTXH","IE0002141913.USD","LU2750360641.GBP","LU1069344957.HKD","LU2756315664.SGD","LU1868836591.USD","CURE","BK4007","LU0320765992.SGD","LU0133085943.USD","LU0234572021.USD","LU0256863902.USD","LU0471298694.HKD","LU2112291526.USD","SG9999015986.USD","WDNA","LU0417517546.SGD","IHE","GB00BDT5M118.USD","LU2106854487.HKD","ELIS","IYH","LU0097036916.USD","SG9999001176.SGD","LU0820562030.AUD","LU0640476718.USD","LU2462157665.USD","LU2360106947.USD","LU1267930730.SGD","LU0058720904.USD","LU2361044949.HKD","LU1983299246.USD","LU2089283258.USD","MEDI","HRTS","LU2028103732.USD","IE0009355771.USD","LU2896262040.SGD","LU2089984988.USD","LU2237443465.HKD","LU0823434740.USD","LU2168564495.EUR","SGXZ57979304.SGD","IE00BJJMRX11.SGD","IE00BWXC8680.SGD","LU1232071149.USD","IE00BFSS7M15.SGD","LU0964807845.USD","IE00B1XK9C88.USD","LU1979441026.SGD","LU0823416689.USD","IE00BJT1NW94.SGD","LU2552382132.HKD","LU0238689110.USD","SG9999014914.USD","AGNG","SG9999015945.SGD","TRUH","LU2602419157.SGD","LU0683600562.USD","LU0345770993.USD","LU2237438978.USD","IE00B4R5TH58.HKD","LU0320765059.SGD","LU2168564149.EUR","SGXZ81514606.USD","LU2023250330.USD","SG9999015978.USD","LLY","LU0079474960.USD","LU1804176565.USD","LU2237443978.SGD","ELIL","LU1366192091.USD","LU1035775433.USD","IE00B2B36J28.USD","BK4599","LU1691799644.USD","LU2168564222.USD","LU1093756325.SGD","OZEM","LU1974910355.USD","LU2236285917.USD","IE00B7KXQ091.USD","IE00BN29S564.USD","LU1629891620.HKD","LU0456855351.SGD","LU1720051108.HKD","LU2456880835.USD","IE00BJLML261.HKD","LU0109394709.USD","IE0001KFT4U8.USD","LU2552382058.USD","LU0466842654.USD","LU1057294990.SGD","PPH","IE00BKDWB100.SGD","MEDX","LU2746668974.SGD","LU1988902786.USD","LLYX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":4,"totalSize":300,"code":"91000000","status":"200"}]}}